###### Key messages

What is already known about this subject?
=========================================

-   Since the 2016 update of the recommendations for the management of rheumatoid arthritis (RA), the body of evidence has grown vividly. Therefore, this systematic literature research (SLR) was performed to inform the 2019 European League against Rheumatism (EULAR) task force with the summarised evidence on efficacy of conventional and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), biological DMARDs and glucocorticoids.

What does this study add?
=========================

-   Trials comparing biological DMARDs have shown similar efficacy, regardless of the underlying mode of action.

-   Head-to-head trials between Janus kinase (JAK) inhibitors (JAKi) and tumour necrosis factor inhibitor inhibitors did not reveal clinically important differences in efficacy.

-   Drug tapering of DMARDs, including JAKi is possible, especially in patients achieving stable remission.

-   Treating patients to target using MRI-defined remission does not lead to better outcomes when compared with a conventional clinical treat-to-target strategy.

How might this impact on clinical practice or future developments?
==================================================================

-   This SLR, alongside with the safety SLR, provided the 2019 EULAR RA management recommendations task force with the emerged evidence since 2016.

Introduction {#s1}
============

To provide the task force on the 2019 update of the European League against Rheumatism (EULAR) recommendations for the pharmacological management of rheumatoid arthritis (RA) with all available evidence that had emerged since the last update, systematic literature researches (SLRs) were performed. In 2016, three SLRs were conducted assessing efficacy of biological disease-modifying antirheumatic drugs (bDMARDs),[@R1] efficacy of glucocorticoids (GCs), conventional synthetic (cs) and targeted synthetic (ts) DMARDs,[@R2] and safety of pharmacological treatments in RA.[@R3] The 2019 update was based on two SLRs, one on safety and the present one on efficacy of pharmacological interventions in RA.

The body of evidence has grown vividly in the last 3 years, especially regarding tsDMARDs inhibiting Janus Kinase inhibitor (JAKi), novel bDMARDs targeting new as well as established pathways and trials comparing bDMARDs to other bDMARDs or tsDMARDs, providing important information on the comparative efficacy of these compounds.[@R4] Further, studies on tapering and stopping treatment broaden the information base for rheumatologists and patients on the question of possible disease flares after tapering or cessation of drugs, once patients have reached the clinical target. Strategic studies on how to optimally treat patients to target,[@R5] using clinical and imaging targets have also answered important research questions.[@R6] Finally, a large number of trials compared the efficacy and safety of biosimilars (bs) DMARDs with those of their bio-originators (bo), including switching between boDMARD and respective bsDMARDs.

This SLR was conducted to update the evidence on efficacy of pharmacological interventions in RA. This involves the evidence accrued since the last update of the treatment recommendations for RA, published by EULAR in 2016.[@R7] Another SLR focusing on safety of pharmacological treatments in RA is published separately.[@R8]

Methods {#s2}
=======

The EULAR updated standard operating procedures were followed,[@R9] and an SLR protocol was developed and approved by the steering committee.

Studies eligible for inclusion in this SLR were randomised, controlled, double-blind trials investigating csDMARDs, bDMARDs (bo and bsDMARDs), tsDMARDs or GCs in adult patients with RA classified according to the 2010 American College of Rheumatology (ACR)/EULAR or the ACR 1987 criteria. This SLR was considered to further update the available evidence since the previous SLRs, therefore, articles published between 1 January 2016 and 8 March 2019 with no language restriction were searched. Additionally, studies presented as conference abstracts at the EULAR and ACR annual meetings from 2016 to 2018 were also eligible for inclusion. References of original articles published on submission of the manuscript (after the data cut), but with respective conference abstracts included before, were included in the reference list.

The initial literature search was conducted by an experienced librarian (LF) using Medline, Embase, The Cochrane CENTRAL Register of Controlled Trials (Central) and the EULAR/ACR abstract archives as information sources. The detailed search strategy for each database is shown in the [online supplementary tables S1.1--S1.6](#SP1){ref-type="supplementary-material"}.
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The study selection process was conducted independently by two investigators (AK and AS) and discussed until agreement was achieved. A senior methodologist (RL) was consulted in the case of uncertainties. After the initial title and abstract screening for identification of reports of potential interest, a detailed assessment for eligibility of preselected articles was done. Data of eligible studies were extracted based on standardised methods using pivotal forms. Variables of interest were predefined in the review protocol, including signs and symptoms of arthritis and commonly used composite measures, respective core set variables, physical function, patient-reported outcomes and measures of structural damage.

Sixteen research questions were defined according to the Patient population, Intervention, Control, Outcome (PICO) principle with the help of the steering committee. All typical RA study populations were included, methotrexate (MTX)-naïve or generally DMARD-naïve patients, csDMARD insufficient responders (IR), bDMARD-IR or tsDMARD-IR. Adequately defined control groups receiving either placebo or active treatment were mandatory for inclusion in this analysis. These involved the efficacy of bDMARDs with or without csDMARD combination, head-to-head comparisons of bDMARDs and switching between different bDMARDs, tapering and stopping bDMARDs, as well as the efficacy of tsDMARDs and the respective head-to-head comparison to bDMARDs. Other research questions involved biosimilars, switching between bsDMARDs and respective boDMARD, the efficacy of csDMARDs and the efficacy of GC (in combination with csDMARDs). All interventions of interest are shown in [online supplementary table S1.7](#SP1){ref-type="supplementary-material"}. A detailed description of the PICOs is shown in [online supplementary table S1.8](#SP1){ref-type="supplementary-material"}.

Risk of bias (RoB) in individual studies was assessed at study level using the Cochrane Collaborations Risk of Bias tool for randomised controlled trials (RCTs). The assessment was done independently by two investigators (AK and AS). Differing assessments were discussed until consensus was reached.

Due to the heterogeneity of the available studies, no meta-analysis was performed, and results will be reported narratively. Descriptive forest plots were created using RevMan V.5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results {#s3}
=======

The study selection process involved 15 037 references. After deduplication, 7876 remained for title and abstract screening, of which 234 were selected for full article review and 136 articles finally included. A detailed flow chart is depicted in [figure 1](#F1){ref-type="fig"}. Details of all studies included are shown in [online supplementary table S2.1](#SP1){ref-type="supplementary-material"}.

![PRISMA flow chart describing the study selection process. DMARDs, disease-modifying antirheumatic drugs; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLR, systematic literature research.](annrheumdis-2019-216656f01){#F1}

RoB was considered as low for most RCTs included. RCTs were rated as having an unclear RoB most commonly due to insufficient reporting of random sequence generation and/or allocation concealment. Due to their unblinded nature, open-label studies were considered as having a high RoB. Trials reported in conference abstracts were not assessed regarding RoB due to limited information. Results of the RoB assessment are shown in [online supplementary table S2.2](#SP1){ref-type="supplementary-material"}.

Characteristics of each trial for which data were extracted (study size, PICOs), baseline characteristics ([online supplementary table S2.3--S2.12](#SP1){ref-type="supplementary-material"}), results of studies and summary data for each intervention group ([online supplementary table S3.1--S3.13](#SP1){ref-type="supplementary-material"}) as well as the respective citations (section 4 in the [online supplementary appendix](#SP1){ref-type="supplementary-material"}) are shown in the supplement. A summary of included trials and therapies investigated is shown in [table 1](#T1){ref-type="table"}.

###### 

Interventions and therapeutic compounds of trials included for review

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intervention                                                                                                                   No of articles/ abstracts\*                    Therapeutic compound                                                                            Target
  ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  **csDMARDs, csDMARD combination, Glucocorticoids versus other csDMARDs or placebo** ([@R10])                                   5                                              Tacrolimus +methotrexate (MTX) versus leflunomide+MTX                                           FKBP12; dihydrofolate reductase +purine metabolism; dihydroorotate dehydrogenase

  MTX+sulfasalazine + glucocorticoids versus MTX +glucocorticoids versus MTX +Leflunomide +Glucocorticoids                                                                                                                                                                      

  MTX versus MTX+glucocorticoids                                                                                                                                                                                                                                                

  MTX+sulfasalazine + Hydroxychloroquine versus leflunomide +sulfasalazine + hydroxychloroquine versus leflunomide monotherapy                                                                                                                                                  

  **bDMARD ±csDMARDs versus placebo**\                                                                                           21                                             BCD-020                                                                                         CD-20
  ([@R13])                                                                                                                                                                                                                                                                      

  SBI-087                                                                                                                                                                                                                                                                       

  Tregalizumab                                                                                                                   CD-4                                                                                                                                           

  Abatacept                                                                                                                      CD-80/CD-86                                                                                                                                    

  Certolizumab pegol                                                                                                             TNF                                                                                                                                            

  Olokizumab                                                                                                                     IL-6                                                                                                                                           

  Sirukumab                                                                                                                                                                                                                                                                     

  Sarilumab                                                                                                                      IL-6 receptor                                                                                                                                  

  Vobarilizumab                                                                                                                                                                                                                                                                 

  CNTO6785                                                                                                                       IL-17                                                                                                                                          

  Secukinumab                                                                                                                                                                                                                                                                   

  Otilimab                                                                                                                       GM-CSF                                                                                                                                         

  Mavrilimumab                                                                                                                   GM-CSF receptor                                                                                                                                

  Ustekinumab                                                                                                                    IL-12/23                                                                                                                                       

  Guselkumab                                                                                                                     IL-23                                                                                                                                          

  **bDMARDs versus other bDMARDs** ([@R4])                                                                                       8                                              Rituximab versus etanercept/adalimumab                                                          CD-20 versus TNF

  ABT-122 versus adalimumab                                                                                                      TNF/IL-17A versus TNF                                                                                                                          

  Certolizumab pegol versus adalimumab                                                                                           TNF                                                                                                                                            

  Sirukumab versus adalimumab                                                                                                    IL-6 versus TNF                                                                                                                                

  Sarilumab versus adalimumab                                                                                                    IL-6 receptor versus TNF                                                                                                                       

  Secukinumab versus abatacept                                                                                                   IL-17 versus CD-80/CD-86                                                                                                                       

  Mavrilimumab versus golimumab                                                                                                  GM-CSF versus TNF                                                                                                                              

  **bDMARD induction versus csDMARD induction in early disease** ([@R69])                                                        5                                              Certolizumab pegol versus MTX                                                                   TNF

  Abatacept versus MTX                                                                                                           CD-80/CD-86                                                                                                                                    

  Infliximab versus MTX                                                                                                          TNF                                                                                                                                            

  Tocilizumab versus MTX                                                                                                         IL-6 receptor                                                                                                                                  

  **Switching between bDMARDs** ([@R4])                                                                                          3                                              Certolizumab pegol versus adalimumab                                                            TNF

  Abatacept; rituximab; tocilizumab versus adalimumab; certolizumab; infliximab; golimumab; etanercept                           CD-80/CD-86; CD-20; IL-6 receptor versus TNF                                                                                                   

  Sarilumab                                                                                                                      IL-6 receptor                                                                                                                                  

  **Tapering of bDMARDs/tsDMARDs or csDMARDs** ([@R107])                                                                         25                                             Abatacept                                                                                       CD-80/CD-86

  Tocilizumab                                                                                                                    IL-6 receptor                                                                                                                                  

  Adalimumab; certolizumab pegol; etanercept; infliximab;                                                                        TNF                                                                                                                                            

  csDMARDs                                                                                                                                                                                                                                                                      

  Glucocorticoids                                                                                                                                                                                                                                                               

  **Strategic studies** ([@R6])                                                                                                  2                                                                                                                                               

  **tsDMARDs±csDMARDs versus placebo** ([@R73])                                                                                  32                                             Baricitinib                                                                                     JAK 1/2

  Decernotinib                                                                                                                   JAK 3                                                                                                                                          

  Filgotinib                                                                                                                     JAK 1                                                                                                                                          

  GS-9876                                                                                                                        SYK                                                                                                                                            

  Peficitinib                                                                                                                    JAK 1                                                                                                                                          

  Tofacitinib                                                                                                                    JAK 1/3                                                                                                                                        

  Upadacitinib                                                                                                                   JAK 1                                                                                                                                          

  **tsDMARDs±csDMARDs versus bDMARDs±csDMARDs** ([@R101])                                                                        5                                              Baricitinib versus adalimumab                                                                   JAK 1/2 versus TNF

  Tofacitinib versus adalimumab                                                                                                  JAK 1/3 versus TNF                                                                                                                             

  Upadacitinib versus adalimumab                                                                                                 JAK 1 versus TNF                                                                                                                               

  **bsDMARDs versus boDMARDs** ([@R30])                                                                                          24                                             Adalimumab: ABP 501, AdaliRel, BI 695501, CinnoRA, FKB327, GP2017, PF-06410293, SB5, ZRC 3197   TNF

  Etanercept: CHS-0214, GP2015, HD203, LBEC0101                                                                                  TNF                                                                                                                                            

  Infliximab: BCD-055, CT-P13, NI-071, PF-06438179/GP1111, SB2                                                                   TNF                                                                                                                                            

  Rituximab: BCD-020, CT-P10, DRL-RI, GP2013                                                                                     CD-20                                                                                                                                          

  **Switching between bsDMARDs and boDMARDs** ([@R32])                                                                           6                                              Adalimumab: SB5                                                                                 TNF

  Etanercept: GP2015, CHS-0214, LBEC0101                                                                                         TNF                                                                                                                                            

  Infliximab: SB2, CT-P13                                                                                                        TNF                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Studies answering multiple research questions account for mismatch between included articles/abstracts and numbers in this table. References of manuscripts published after the SLRs data cut, with the respective conference abstracts included before, are shown, but were not counted.

bDMARD, biological disease-modifying antirheumatic drug; boDMARD, biooriginator disease-modifying antirheumatic drug; bsDMARD, biosimilar disease-modifying antirheumatic drug; CD, cluster of differentiation; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; JAK, Janus kinase; SYK, spleen tyrosine kinase; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.

Efficacy of csDMARDs (or combination of csDMARDs) versus other csDMARDs {#s3-1}
-----------------------------------------------------------------------

Five trials (all with unclear or high RoB) investigated the efficacy of csDMARDs alone or in combination versus other csDMARDs (see [table 1](#T1){ref-type="table"}). Baseline characteristics and detailed results are shown in [online supplementary table S2.12](#SP1){ref-type="supplementary-material"} and [online supplementary table S3.13](#SP1){ref-type="supplementary-material"}, respectively.

The open-label CareRA trial (high RoB) stratified very early, csDMARD naive patients based on their risk factors (presence of erosions, disease activity, rheumatoid factor and anticitrullinated protein antibodies) into high and low risk.[@R10] High-risk patients were randomised to three different csDMARD regimens (Combination therapy for early Rheumatoid Arthritis (COBRA) classic: methotrexate (MTX)+sulfasalazine (SSZ) + prednisone 60 mg step-down vs COBRA Slim: MTX+prednisone 30 mg step-down vs COBRA Avant Garde: MTX+leflunomide (LEF) + prednisone 60 mg step-down). Low-risk patients were either randomised to MTX tight-step up or COBRA Slim). The treatment arms investigated in high-risk patients showed comparable efficacy in achieving the primary endpoint (Disease Activity Score of 28 joints (DAS28)-C reactive protein (CRP) \<2.6) at week 52 for COBRA Classic (64.3%, 63/98).

COBRA Slim (60.2%, 59/98) and COBRA Avant Garde (62.4%, 58/93, p=0.840). In low-risk patients, COBRA-Slim and MTX-tight step up also showed comparable efficacy at week 52 (67.4%, 29/43 vs 57.4%, 27/47, p=0.329). However, the area under the curves for mean DAS28-CRP change from baseline as well as time-to-remission were favouring MTX plus prednisone combination therapy. Radiographic damage was minimal and comparable across all treatment arms. Sustained and comparable efficacy was shown after 2 years of treatment in high-risk patients.[@R11]

Investigation of LEF plus SSZ plus hydroxychloroquine (HCQ) triple therapy compared with MTX+SSZ+ HCQ triple therapy or LEF alone in a 48-week double-blind RCT was terminated early due to gastrointestinal complications in the LEF +SSZ+ HCQ arm. Conventional triple therapy (MTX+SSZ+ HCQ) was superior to LEF +SSZ+ HCQ and LEF alone (ACR20: 87% vs 46%, p\<0.01, 87% vs 36%, p\<0.001, respectively), with no apparent efficacy benefit of the LEF triple therapy compared with LEF alone at week 48 (ACR20: 46% vs 36%, p\>0.05).[@R12]

Efficacy of bDMARDs, alone or in combination with csDMARDs, in csDMARD and bDMARD-IR patients with (established) RA {#s3-2}
-------------------------------------------------------------------------------------------------------------------

Trials comparing bDMARDs to placebo with or without csDMARD background therapy (21 articles/abstracts, 7 with low RoB) showed effective reduction of signs and symptoms for several different modes of action (see [table 1](#T1){ref-type="table"}), including molecules targeting B-cells (SBI-087, BCD-020),[@R13] interferon-6 (IL-6) receptor (sarilumab),[@R15] IL-6 cytokine (sirukumab, olokizumab, vobarilizumab),[@R17] GM-CSF receptor (mavrilimumab) and GM-CSF cytokine (otilimab).[@R23] IL-12/23 inhibition (ustekinumab) and IL23i (guselkumab) did not show significant differences from placebo. Molecules targeting IL-17A (secukinumab, CNTO6785),[@R26] and CD4 (tregalizumab) showed no or only minor efficacy compared with placebo (and lower efficacy compared with abatacept (ABA) as active comparator) in different patient populations.[@R29] Primary efficacy outcomes are summarised in [table 2](#T2){ref-type="table"}, baseline characteristics are shown in [online supplementary table S2.3](#SP1){ref-type="supplementary-material"} and secondary efficacy outcomes in [online supplementary table S3.1](#SP1){ref-type="supplementary-material"}.

###### 

Primary efficacy outcomes of trials comparing biological DMARDs with or without background csDMARD therapy to placebo

  Study                                         Risk of bias   Treatment                    N         Time point (weeks)   Primary endpoint                   Outcome    P value
  --------------------------------------------- -------------- ---------------------------- --------- -------------------- ---------------------------------- ---------- -----------
  Damjanov 2016[@R13]                           High           Pbo/Pbo/Pbo+MTX              40        16                   ACR 20 (%)                         NR         Reference
  SBI-087/Pbo/Pbo+MTX                           43             NR                           NS                                                                           
  SBI-087/SBI-087/Pbo+MTX                       42             NR                           NS                                                                           
  SBI-087/Pbo/SBI-087+MTX                       43             NR                           NS                                                                           
  SBI-087/SBI-087/SBI-087+MTX                   41             NR                           0.046                                                                        
  Mazurov 2018[@R14]                            Abstract       Placebo +MTX                 52        24                   ACR 20 (%)                         29         Reference
  BCD-020 600 mg+MTX                            107            66                           \<0.001                                                                      
  Fleischmann 2017 (TARGET)[@R15]               Low            Placebo +csDMARDs            181       12/24                ACR 20 (%) / ΔHAQ-DI               34/−0.3    Reference
  SLM 150 mg Q2W+csDMARDs                       181            56/−0.5                      \<0.001                                                                      
  SLM 200 mg Q2W+csDMARDs                       184            61/−0.6                      \<0.001                                                                      
  Tanaka 2018b (KAKEHASI)[@R16]                 Abstract       Placebo +MTX                 82        24                   ACR 20 (%)                         15         Reference
  SLM 150 mg Q2W+MTX                            81             68                           \<0.001                                                                      
  SLM 200 mg Q2W+MTX                            80             58                           \<0.001                                                                      
  Aletaha 2017 (SIRROUND-T)[@R17]               Low            Placebo±csDMARDs             294       16                   ACR 20 (%)                         24         Reference
  SKM 50 mg Q4W±csDMARDs                        292            40                           \<0.001                                                                      
  SKM 100 mg Q2W±csDMARDs                       292            45                           \<0.001                                                                      
  Takeuchi 2017 (SIRROUND-D)[@R19]              Unclear        Placebo +csDMARD             556       16/52                ACR 20 (%)/ΔmTSS                   26/1.96    Reference
  SKM 50 mg Q4W+csDMARD                         557            55/0.35                      \<0.001                                                                      
  SKM 100 mg Q2W+csDMARD                        557            54/0.3                       \<0.001                                                                      
  Takeuchi 2016 (RA0083)[@R20]                  Low            Placebo +MTX                 29        12                   ΔDAS28-CRP                         −0.64      Reference
  OKZ 60 mg Q4W+MTX                             32             −2.18                        \<0.001                                                                      
  OKZ 120 mg Q4W+MTX                            32             −2.45                        \<0.001                                                                      
  OKZ 240 mg Q4W+MTX                            36             −2.68                        \<0.001                                                                      
  Dorner 2017[@R21]                             Abstract       (Open-Label) TCZ 162 mg QW   60        12                   ACR 20 (%), no formal comparison   78         NR
  VBM 150 mg Q4W                                62             73                                                                                                        
  VBM 150 mg Q2W                                62             77                                                                                                        
  VBM 225 mg Q2W                                63             81                                                                                                        
  Weinblatt 2017[@R22]                          Abstract       Placebo +MTX                 69        12                   ACR 20 (%)                         62         Reference
  VBM 75 mg Q4W+MTX                             69             75                           NS                                                                           
  VBM 150 mg Q4W+MTX                            70             81                           NS                                                                           
  VBM 150 mg Q2W                                68             78                           NS                                                                           
  VBM 225 mg Q2W                                69             72                           NS                                                                           
  Burmester 2017b (EARTH EXPLORER 1)[@R23]      Low            Placebo +MTX                 81        12/24                ACR 20 (%)/ΔDAS28-CRP              25/−0.68   Reference
  MVM 150 mg Q2W+MTX                            79             51/−1.9                      \<0.001                                                                      
  MVM 100 mg Q2W+MTX                            85             61/−1.64                     \<0.001                                                                      
  MVM 30 mg Q2W+MTX                             81             73/−1.37                     \<0.001                                                                      
  Buckley ACR 2018[@R24]                        Abstract       Placebo +MTX                 37        12                   DAS28-CRP \<2.6 (%)                3          Reference
  OTM 22.5 mg +MTX                              37             5                            0.547                                                                        
  OTM 45 mg+MTX                                 37             16                           0.077                                                                        
  OTM 90 mg+MTX                                 37             19                           0.053                                                                        
  OTM 135 mg+MTX                                37             14                           0.122                                                                        
  OTM 180 mg+MTX                                37             14                           0.134                                                                        
  Tahir 2017 (REASSURE)[@R26]                   Unclear        Placebo±MTX                  214       24                   ACR 20 (%)                         19.6       Reference
  SEC 3×10 mg/kg i.v. Q2W/150 mg s.c. Q4W±MTX   213            35                           \<0.001                                                                      
  SEC 3×10 mg/kg i.v. Q2W/75 mg s.c. Q4W±MTX    210            35                           \<0.001                                                                      
  Mease 2018[@R27]                              Unclear        Placebo +MTX                 51        16                   ACR 20 (%)                         41         Reference
  CNTO6785 15 mg Q4W+MTX                        52             52                           NS                                                                           
  CNTO6785 50 mg Q4W+MTX                        51             47                           NS                                                                           
  CNTO6785 100 mg Q4W+MTX                       51             37                           NS                                                                           
  CNTO6785 200 mg Q4W+MTX                       52             40                           NS                                                                           
  Dokoupilova 2018 (REASSURE2)[@R28]            Unclear        Placebo +csDMARDs            81        24                   ACR 20 (%)                         27         Reference
  SEC 150 mg+csDMARDs                           81             38                           0.157                                                                        
  SEC 75 mg+csDMARDs                            80             38                           0.200                                                                        
  van Vollenhoven 2018[@R29]                    Low            Placebo +MTX                 79        12                   ACR 20 (%)                         35         Reference
  TLM 25 mg+MTX                                 80             42                           0.395                                                                        
  TLM 100 mg+MTX                                78             47                           0.165                                                                        
  TLM 200 mg+MTX                                76             44                           0.274                                                                        
  Bi 2018 (RAPID-C)[@R132]                      High           Placebo +MTX                 113       24                   ACR 20 (%)                         24         Reference
  CZP +MTX                                      316            55                           \<0.001                                                                      
  Smolen 2017a[@R133]                           Low            Placebo +MTX                 55        28                   ACR 20 (%)                         40         Reference
  UKM 90 mg Q8W+MTX                             55             53                           0.877                                                                        
  UKM 90 mg Q12W+MTX                            55             55                                                                                                        
  GKM 50 mg Q8W+MTX                             55             38                           0.101                                                                        
  GKM 200 mg Q8W+MTX                            54             44                                                                                                        

Detailed results of risk of bias analyses are shown in [online supplementary table S2.2](#SP1){ref-type="supplementary-material"} in the supplementary appendix.

Δ, change from baseline; ACR, American College of Rheumatology response criteria; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; CZP, certolizumab pegol; DAS28-CRP, Disease Activity Score of 28 joints with C-reactive protein; GKM, guselkumab; HAQ-DI, Health Assessment Questionnaire Disability Index; i.v., intravenous; mTSS, modified total Sharp score; MTX, methotrexate; MVM, mavrilimumab; NR, not reported; NS, not significant; OKZ, olokizumab; OTM, Otilimab; Pbo, placebo; s.c., subcutaneous; SEC, secukinumab; SKM, sirukumab; SLM, sarilumab; TCZ, tocilizumab; TLM, tregalizumab; UKM, ustekinumab; VBM, vobarilizumab.

Trials comparing bsDMARDs to boDMARDs {#s3-3}
-------------------------------------

Twenty-four non-inferiority trials (12 with low RoB) investigated the bioequivalence of bsDMARDs to their respective boDMARDs. All showed conclusive comparable results, irrespective of the compound (adalimumab (ADA), etanercept, infliximab and rituximab; for bsDMARD studied see [table 1](#T1){ref-type="table"}, [online supplementary table S2.10](#SP1){ref-type="supplementary-material"} and [online supplementary table S3.11](#SP1){ref-type="supplementary-material"}).[@R30]

Switching between biosimilars and bio-originators revealed no changes in efficacy in trials of one ADA (SB5, low RoB),[@R56] three etanercept (two with low RoB: GP2015, LBEC0101; CHS-0214: conference abstract---RoB not assessed),[@R32] and two infliximab biosimilars (SB2, CT-P13, both low RoB).[@R60] Detailed characteristics and results of the studies are shown in [online supplementary tables S2.11 and S3.11](#SP1){ref-type="supplementary-material"}.

Head-to-head studies (bDMARDs) {#s3-4}
------------------------------

Seven bDMARD head-to-head studies were included (six with low RoB; one high RoB). Efficacy results are summarised in [table 3](#T3){ref-type="table"} (baseline characteristics and detailed efficacy outcomes are shown in [online supplementary tables S2.3 and S3.2](#SP1){ref-type="supplementary-material"}.).

###### 

Head-to-head studies comparing bDMARDs to other bDMARDs

  Population                                   Study                                       Risk of bias        Treatment          N                                    Primary endpoint                                        P value                         ACR20 (%)   ACR50 (%)   ACR70 (%)   DAS28 \<2.6 (%)   CDAI ≤2.8 (%)   ΔHAQ
  -------------------------------------------- ------------------------------------------- ------------------- ------------------ ------------------------------------ ------------------------------------------------------- ------------------------------- ----------- ----------- ----------- ----------------- --------------- -------
  **MTX-IR**                                   Burmester 2017 (MONARCH)[@R63]              Low                 ADA 40 mg Q2W      185                                  ΔDAS28-ESR at week 24                                   \<0.001                         58          30          12          7                 3               −0.43
  SLM 200 mg Q2W                               184                                         72                  46                 23                                   27                                                      7                               −0.61                                                                 
  Smolen 2016 (EXXELERATE)[@R4]                Low                                         ADA 40 mg Q2W+MTX   454                ACR 20 (%) at week 12                0.532                                                   71                                                                  22                                
  CZP 400/200 mg Q2W+MTX                       454                                         69                                                                                                                                  25                                                                                                    
  Taylor 2018 (SIRROUND-H)[@R66]               Low                                         ADA 40 mg Q2W       186                ACR 50 (%) + ΔDAS28-ESR at week 24   Reference                                               57                              32          13          8                             −0.52           
  SKM 50 mg Q4W                                186                                         0.306/0.013         54                 27                                   12                                                      13                                          −0.51                                                     
  SKM 100 mg Q2W                               187                                         0.464/ \<0.001      59                 35                                   16                                                      20                                          −0.53                                                     
  Genovese 2018b[@R65]                         Low                                         ADA 40 mg Q2W+MTX   56                 ACR 20 (%) at week 12                Reference                                               68                              48          21          30          7                 −0.6            
  ABT-122 60 mg Q2W+MTX                        55                                          0.863               62                 35                                   22                                                      22                              7           −0.6                                                      
  ABT-122 120 mg Q2W+MTX                       56                                          0.414               75                 46                                   18                                                      38                              11          −0.6                                                      
  ABT-122 120 mg QW +MTX                       55                                          0.196               80                 47                                   36                                                      42                              11          −0.9                                                      
  **csDMARD-IR**                               Porter 2016 (ORBIT)[@R62]                   High                Anti-CD20 (RTX)    140                                  ΔDAS28-ESR (non-inferiority) at week 52                 0.24                            66          49          23          23                                −0.49
  TNFi (ETA/ADA)                               134                                         71                  45                 26                                   21                                                                                      −0.38                                                                 
  **TNF-IR**                                   Blanco 2017 (NURTURE 1)[@R138]              Low                 Placebo +csDMARD   138                                  ACR 20 (%) at week 24                                   Reference                       18          9           5                                             −0.3
  ABA 500/750/1000mg+csDMARD                   138                                         \<0.05              43                 28                                   12                                                                                                  −0.6                                                      
  SEC 10 mg/kg i.v. +150 mg s.c. Q4W+csDMARD   137                                         0.031               31                 17                                   10                                                                                                  −0.4                                                      
  SEC 10 mg/kg i.v. +75 mg s.c. Q4W+csDMARD    138                                         0.092               28                 12                                   5                                                                                                   −0.3                                                      
  **Mixed cs/bDMARD-IR**                       Weinblatt 2018 (EARTH EXPLORER 2)\*[@R64]   Low                 GLM 50 mg Q4W      68                                   ACR 20/50/70%, DAS28-CRP \<2.6, ΔHAQ\>0.22 at week 24   0.666/0.293/0.156/0.108/0.208   66          43          26          29                18              −0.64
  MVM 100 mg Q2W+MTX                           70                                          62                  35                 16                                   17                                                      6                               −0.44                                                                 

Results of secondary efficacy outcomes are shown at the time point of the primary endpoint.

\*Study not powered to formally compare the treatments. Detailed results of risk of bias analyses are shown in [online supplementary table S2.2](#SP1){ref-type="supplementary-material"} in the supplementary appendix.

Δ, change from baseline; ABA, abatacept; ACR, American College of Rheumatology; ADA, adalimumab; bDMARDs, biological disease-modifying antirheumatic drugs; CDAI, clinical disease activity index; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; CZP, certolizumab pegol; DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; ETA, etanercept; GLM, golimumab; HAQ, Health Assessment Questionnaire; i.v., intravenous; MTX, methotrexate; MVM, mavrilimumab; RTX, rituximab; SEC, secukinumab; SKM, sirukumab; SLM, sarilumab; TNFi, TNF inhibitor; TNF-IR, tumour necrosis factor-insufficient responder.

The Optimal Management of patients with rheumatoid arthritis who Require Biologic Therapy (ORBIT) trial (high RoB), an open-label non-inferiority RCT comparing B-Cell depletion (rituximab) to tumour necrosis factor inhibitor (TNFi) therapy in csDMARD-IR and bDMARD-naïve patients, found that RTX is non-inferior to TNFi over 52 weeks regarding clinical efficacy.[@R62]

Sarilumab monotherapy showed clinical and functional superiority compared with ADA monotherapy in patients who were intolerant or inadequately responding to MTX.[@R63]

Mavrilimumab (targeting GM-CSFR) was compared with golimumab in a 24-week phase 2b trial of csDMARD and/or TNFi-IR patients and had similar efficacy.[@R64]

ABT-122, a bispecific dual variable domain immunoglobulin targeting TNF and IL-17A, exhibited similar efficacy rates in the 120 mg arm as ADA in MTX-IR patients over 12 weeks.[@R65]

The SIRROUND-H study investigated superiority of sirukumab (IL-6i) monotherapy over ADA monotherapy in MTX-IR, bDMARD naive patients. The study failed to meet one of its coprimary endpoints with no significant differences in ACR50% response rates at week 24; the other primary endpoint (DAS28-ESR mean change from baseline at week 24) was met.[@R66]

The EXXELERATE study did not show superiority of certolizumab pegol compared with ADA and therefore failed to meet its primary endpoint, showing similar ACR20% response rates at week 12.[@R4]

Switching between different bDMARDs {#s3-5}
-----------------------------------

Three trials on switching between different bDMARDs were included (see [online supplementary table S2.4](#SP1){ref-type="supplementary-material"} and [online supplementary table S3.3](#SP1){ref-type="supplementary-material"} for details).

EXXELERATE also studied the efficacy of single-blinded switching to a second TNFi (without washout) in patients with primary non-response to either certolizumab pegol or ADA (unclear RoB). Twelve weeks after switching 58% (ADA to certolizumab pegol) and 62% (certolizumab pegol to ADA) of patients achieved DAS28-ESR≤3.2 or a DAS28-ESR reduction of 1.2 or more.[@R4]

An exploratory analysis of the EXTEND trial, an open-label extension study of the ASCERTAIN trial, investigated patients switched from tocilizumab (TCZ) to sarilumab (conference abstract). After 12 and 24 weeks about one-third of patients non-responders to TCZ achieved clinical response (Clinical Disease Activity Index (CDAI) ≤10; ACR70) after switching to sarilumab.[@R67]

The open-label ROC trial (high RoB) investigated patients who failed one TNFi therapy, comparing non-TNFi therapies (ABA, RTX, TCZ) to a second TNFi drug. The primary efficacy endpoint, superiority in EULAR good or moderate response at week 24, was met with higher responses in the non-TNFi group (101/146, 69%) compared with 52% in the second TNFi group (OR 2.12; 95% CI 1.31 to 3.46; p=0.003).[@R68] bDMARD therapies in early RA patients.

Five reports on induction therapy with bDMARDs in early disease were included (two with low RoB), baseline characteristics are shown in [online supplementary table S2.5](#SP1){ref-type="supplementary-material"} and results in [online supplementary table S3.4](#SP1){ref-type="supplementary-material"}.

In DMARD naïve patients with poor prognostic factors, CZP in combination with dose optimised MTX (C-EARLY) was shown to be superior to placebo +MTX, with 28.9% of patients achieving sustained DAS28 \<2.6 at week 40 and week 52 in the combination arm compared with 15% of patients in the MTX arm.[@R69]

In the AVERT-2 study, ABA+MTX did not show superiority to placebo +MTX regarding SDAI remission (≤3.3) at week 24 (21.3% ABA+MTX vs 16% placebo +MTX), the primary efficacy endpoint.[@R70]

DINORA compared infliximab +MTX treatment to MTX or placebo treatment only. INF+MTX showed superiority to placebo only, but not to MTX monotherapy, in achieving sustained remission (no swollen joints, ≤2 tender joints and an acute phase within the normal range) after 1 year (32% vs 14% vs 0% for INF+MTX, MTX and placebo, respectively).[@R71]

TCZ monotherapy as well as combination therapy of TCZ with MTX was clinically superior to MTX therapy in early RA patients. Inhibition of radiographic damage was found to be significantly greater with 8 mg/kg TCZ intravenous +MTX than in the MTX monotherapy arm modified total Sharp score (ΔmTSS 0.08 vs 1.14). TCZ 8 mg/kg intravenous monotherapy showed less radiographic progression than MTX monotherapy (ΔmTSS 0.26 vs 1.14, p value not reported).[@R72]

Efficacy of tsDMARDs (JAKi) {#s3-6}
---------------------------

In total, 32 articles/abstracts on tsDMARDs were included (see [table 1](#T1){ref-type="table"}); 16 trials were regarded as having low RoB. Baseline characteristics and efficacy outcomes are shown in [online supplementary tables S2.8 and S3.9](#SP1){ref-type="supplementary-material"}, respectively.

Decernotinib (JAK-3i) and peficitinib (non-selective JAKi) were effective as monotherapy and in combination with csDMARDs or MTX in various populations.[@R73]

Filgotinib (JAK-1 selective JAKi) was effective in reducing signs and symptoms of RA as well as improving physical function and patients quality of life in two phase II studies investigating MTX-IR patients in combination with MTX (DARWIN 1) and as monotherapy (DARWIN 2).[@R83]

GS-9876, an oral spleen tyrosine kinase inhibitor did not show clinical efficacy compared with placebo.[@R84]

Baricitinib (BARI) (JAK-1/2i) showed efficacy compared with placebo in csDMARD-IR (RA-BUILD) patients,[@R85] MTX-IR patients,[@R87] and in early RA as monotherapy or in combination with MTX.[@R89]

Upadacitinib proved to be efficacious versus placebo in phase 3 trials of various RA populations, MTX-naive,[@R91] csDMARD/MTX-IR,[@R92] bDMARD-IR (SELECT-BEYOND)[@R99] and tsDMARD versus bDMARD head-to-head trials.

Five reports on three different head-to-head trials (three with low RoB) comparing tsDMARDs to ADA were included. Baseline characteristics are shown in [online supplementary table S2.9](#SP1){ref-type="supplementary-material"} and detailed efficacy results in [online supplementary table S3.10](#SP1){ref-type="supplementary-material"}.

In RA-BEAM, BARI 4 mg+MTX was shown to be superior to ADA 40 mg Q2W+MTX clinically (ACR20 at week 12: 70% vs 61%, p=0.014; ΔDAS28-CRP at week 12: −2.24 vs −1.95, p\<0.001) and functionally (ΔHAQ at week 12: −0.66 vs −0.56, p≤0.01). Regarding structural progression, ADA and BARI were superior compared with placebo (change from baseline in mTSS at week 24: BARI: 0.41 vs ADA: 0.33 vs placebo: 0.9, p vs placebo \<0.001).[@R101] Regarding core set variables, the differences related to patient reported outcomes and CRP, but not to swollen joint counts (SJCs).

ORAL strategy investigated the non-inferiority of tofacitinib 5 mg two times per day with or without MTX compared with ADA 40 mg Q2W+MTX. Non-inferiority was demonstrated for tofacitinib +MTX versus ADA +MTX (ACR50 at week 24: 46% vs 44%, difference: 2%; 98.34% CI −6% to 11%), but not for tofacitinib monotherapy versus ADA +MTX (ACR50 at week 24: 38% vs 44%; −6% (−14%--3%)) or versus tofacitinib +MTX (ACR 50 at week 24: 38% vs 46%; −8% (−16%--1%)).[@R103]

Upadacitinib+MTX was shown to be superior to ADA +MTX in SELECT-COMPARE in both coprimary endpoints (ACR20 at week 12: 70.5% vs 63%, p\<0.05; DAS28-CRP\<2.6 at week 12: 28.7% vs 18%, p\<0.001), with radiographic superiority of upadacitinib +MTX vs placebo +MTX (ΔmTSS at week 26: 0.24 vs 0.92, p\<0.001) and numerically similar results between upadacitinib +MTX and ADA +MTX (ΔmTSS at week 26: 0.24 vs 0.10).[@R105] Also in this study, the differences related to patient-reported outcomes and CRP, but not to SJCs.

Key outcomes are summarised in [table 4](#T4){ref-type="table"}. [Figure 2](#F2){ref-type="fig"} shows descriptive forest plots using ACR 20/50 and 70 response rates. [Figure 3](#F3){ref-type="fig"} summarises outcomes of trials investigating the efficacy of bDMARDs and tsDMARDs (based on their mode of action) compared with placebo.

![Forest plots showing risk ratios of ACR 20, 50 and 70 responses in trials comparing JAK inhibitors+MTX to adalimumab +MTX in MTX-IR patients. 1, tofacitinib; 2, upadacitinib; 3, baricitinib. ACR, American College of Rheumatology; IR, insufficient responder; M-H, Mantel-Haenszel; MTX, methotrexate; JAK, Janus kinase.](annrheumdis-2019-216656f02){#F2}

![Efficacy of different targets of biological and targeted synthetic disease-modifying drugs compared against placebo, shown across major clinical trial outcomes of randomised controlled trials published from 2016 to 2018. ACR, American College of Rheumatology response criteria; CD, cluster of differentiation; DMARD, disease-modifying antirheumatic drugs; EULAR, European League against Rheumatism; GM-CSF, colony-stimulating factor; HAQ, Health Assessment Questionnaire; IL, interleukin; JAK, Janus kinase; mTSS, modified total Sharp score; Syk, spleen tyrosine kinase; TNF, tumour necrosis factor.](annrheumdis-2019-216656f03){#F3}

###### 

Major efficacy outcomes of head-to-head studies comparing JAK inhibitors to adalimumab

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                       Study design   Risk of bias   Treatment           N     Primary endpoint                       P value                              ACR20 (%)   ACR 50 (%)   ACR 70 (%)   DAS28 \<2.6 (%)   CDAI ≤2.8 (%)   ACR/EULAR Boolean rem. (%)   ΔHAQ    ΔmTSS
  ----------------------------------------------------------- -------------- -------------- ------------------- ----- -------------------------------------- ------------------------------------ ----------- ------------ ------------ ----------------- --------------- ---------------------------- ------- -------
  Taylor/Keystone 2017 (RA-BEAM)[@R101]                       S              Low            Placebo +MTX        488   ACR 20 (%) at week 12                  BARI versus PLC:\<0.001;\            40          17           5            4                 2               1                            −0.34   0.9\*
                                                                                                                                                             BARI versus ADA \<0.01                                                                                                                            

  BARI 4 mg+MTX                                               487            70             45                  19    24                                     8                                    7           −0.66        0.41\*                                                                              

  ADA 40 mg Q2W+MTX                                           330            61             35                  13    19                                     7                                    5           −0.56        0.33\*                                                                              

  Fleischmann 2017/Strand EULAR 2018 (ORAL-Strategy)[@R103]   NI             Low            ADA 40 mg Q2W+MTX   386   ACR 50 (%) at week 24                  Reference                            71          44           21           28                13              9                            −0.54   NR

  TOFA 5 mg two times per day+PLC                             384            0.051          65                  38    18                                     21                                   10          7            −0.52        NR                                                                     

  TOFA 5 mg two times per day+MTX                             376            \<0.001        73                  46    25                                     31                                   14          8            −0.58        NR                                                                     

  Fleischmann ACR 2018 (SELECT-COMPARE)[@R105]                S              Low            Placebo +MTX        651   ACR 20 (%)+DAS28-CRP\<2.6 at week 12   UPA versus PLC:\<0.001 / \<0.001;\   36          15           5            6                 3               2                            −0.28   0.92†
                                                                                                                                                             UPA versus ADA:\<0.05/\<0.001                                                                                                                     

  ADA 40 mg Q2W+MTX                                           327            63             29                  14    18                                     8                                    4           −0.49        0.1†                                                                                

  UPA 15 mg OD +MTX                                           651            71             45                  25    29                                     13                                   9.8         −0.6         0.24†                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results of secondary efficacy outcomes are shown at the time point of the primary endpoint.

\*Week 24.

†Week 26.

ADA, adalimumab; BARI, baricitinib; CRP, C-reactive protein; DAS28, Disease Activity Score of 28 joints; EULAR, European League against Rheumatism; HAQ, Health Assessment Questionnaire; JAK, Janus kinase; mTSS, modified total Sharp Score; MTX, methotrexate; MTX, methotrexate; NI, non-inferiority; NR, not reported; OD, once daily; PLC, placebo; S, superiority; TOFA, tofacitinib; UPA, upadacitinib.

Strategy trials {#s3-7}
---------------

IMAGINE-RA, a non-blinded strategic trial (high RoB) which enrolled patients with stable, controlled disease activity (DAS28-CRP ≤3.2 and no swollen joints), compared an MRI guided with a purely clinical treat-to-target strategy. The trial did not meet its coprimary endpoints at month 24, as no differences in DAS28-CRP\<2.6 rates (85% vs 88%, respectively) or differences in the proportion of patients who had no radiographic progression (66% vs 62%) were observed. However, in the MRI-T2T group, more patients needed treatment escalation (73% vs 17%) and initiation of bDMARD therapy (46% vs 2%) accompanied by higher costs and three times more serious adverse events.[@R6]

Tapering and stopping therapy {#s3-8}
-----------------------------

In total 25 studies (three with low RoB) investigated tapering and/or stopping csDMARD, bDMARD or tsDMARD therapy. Primary results are shown in [table 5](#T5){ref-type="table"}, baseline characteristics are shown in [online supplementary table S2.7](#SP1){ref-type="supplementary-material"} and secondary outcomes are shown in [online supplementary tables S3.6, S3.7 and S3.8](#SP1){ref-type="supplementary-material"}

###### 

Primary outcomes of studies investigating csDMARD, bDMARD and tsDMARD tapering and stopping

  Study                                    Primary outcome                                                                                 Endpoint (week)   Treatment arm                                    N     Result   P value
  ---------------------------------------- ----------------------------------------------------------------------------------------------- ----------------- ------------------------------------------------ ----- -------- ------------------------
  **csDMARD tapering**                                                                                                                                                                                                       
  Kaeley 2016 (MUSICA)[@R107]              Mean DAS28-CRP                                                                                  24                ADA 40 mg Q2W+7.5 mg MTX                         154   4.12     0.014
  ADA 40 mg Q2W+20 mg MTX                  155                                                                                             3.75                                                                              
  Keystone 2016 (CAMEO)[@R144]             ΔDAS28-ESR                                                                                      24                ETN 50 mg QW; MTX discontinuation                98    0.5      0.815
  ETN 50 mg QW +MTX continuation           107                                                                                             0.04                                                                              
  Pope EULAR 2017/ACR 2018/2019[@R108]     ΔDAS28-ESR                                                                                      76                CZP +csDMARD continuation                        37    −2.1     NR
  CZP +csDMARD discontinuation             44                                                                                              −2.1                                                                              
  Burmester ACR 2018 (SEMIRA)[@R111]       ΔDAS28-ESR                                                                                      24                TCZ ±csDMARDs; GC tapering                       131   0.538    \<0.001
  TCZ ±csDMARDs; GC continuation           128                                                                                             −0.075                                                                            
  Pablos 2018 (JUST-ACT)[@R112]            ΔDAS28-ESR week 16 week 28                                                                      28                TCZ 8 mg/kg+MTX                                  82    0.007    95% CI −0.40 to 0.27
  TCZ 8 mg/kg+PLC                          82                                                                                              0.073                                                                             
  Kremer 2018 (COMP-ACT)[@R113]            ΔDAS28-ESR week 24 week 40                                                                      40                TCZ 162 mg s.c. +PLC                             147   0.46     95% CI 0.045 to 0.592
  TCZ 162 mg s.c. +MTX                     147                                                                                             0.14                                                                              
  Edwards 2018 (ACT-TAPER)[@R114]          Pat. Maintaining EULAR good/moderate response from week 24--60                                  60                TCZ 8 mg/kg Q4W+PBO                              136   77%      0.036
  TCZ 8 mg/kg Q4W+MTX                      136                                                                                             65%                                                                               
  Stouten 2018 (CareRA)[@R115]             DAS28-CRP \<2.6                                                                                 65                MTX +LEF-\>MTX 15 mg/week                        32    94%      0.031
  MTX+LEF-\>LEF 20 mg/day                  26                                                                                              73%                                                                               
  **bDMARD tapering**                                                                                                                                                                                                        
  Oba 2017/Tanaka ACR 2018 (RRRR)[@R140]   1-year sustained discontinuation rate of INF                                                    106               INF 3 mg/8 mg/10 mg/kg Q8W based on TNF levels   170   24%      0.631
  INF standard 3 mg/kg Q8W                 167                                                                                             21%                                                                               
  Chatzidionysiou 2016 (ADMIRE)[@R142]     DAS28 \<2.6 at week 28                                                                          28                ADA +MTX continuation                            16    94%      0.001
  ADA discontinuation; MTX monotherapy     16                                                                                              33%                                                                               
  Ghiti Moghadam 2016/2018 (POET)[@R117]   \% of pat. DAS28 ≥3.2 + ΔDAS28 \>0.6 for 1 year                                                 52                Stopping TNFi                                    531   51%      \<0.001
  Continuation of TNFi                     286                                                                                             18%                                                                               
  Atsumi 2017 (C-OPERA)[@R119]             ΔmTSS                                                                                           104               CZP +MTX continuation                            108   0.66     0.001
  Stopping CZP; MTX+PLC                    71                                                                                              3.01                                                                              
  Kaneko 2018 (SURPRISE)[@R121]            TCZ free rate                                                                                   104               stopping TCZ; MTX monotherapy                    49    67%      0.001
  stopping TCZ; No DMARD                   53                                                                                              29%                                                                               
  Weinblatt 2017 (C-EARLY)[@R120]          DAS28-ESR ≤3.2 without flares during week 52--104                                               104               CZP 200 mg Q2W+MTX (standard)                    84    49%      Reference
  CZP 200 mg Q4W+MTX (reduced frequency)   126                                                                                             53%               0.112                                                           
  Placebo +MTX (CZP stopped)               79                                                                                              39%               0.041                                                           
  Ibrahim 2017 (OPTIRRA)[@R122]            Flare rate (ΔDAS28 ≥0.6 + DAS28 \>3.2 + ΔSJC OR ΔDAS28 \>1.2 + DAS28 \>3.2)                     24                TNFi 33% tapering; csDMARD                       26    12%      0.873
  TNFi 66% tapering; csDMARD               21                                                                                              29%               0.097                                                           
  Control; csDMARD continuation            50                                                                                              16%               Reference                                                       
  Bouman 2017 (DRESS)[@R145]               Incidence of major flare (ΔDAS28-CRP \>1.2 or ΔDAS28-CRP \>0.6+DAS28-CRP ≥3.2 for \>12 weeks)   144               TNFi dose reduction extension                    115   17%      3%, 95% CI -10% to 15%
  Usual care extension                     57                                                                                              14%                                                                               
  l'Ami 2018[@R124]                        ∆DAS28-ESR                                                                                      28                ADA 40 mg Q3W±MTX                                27    −0.14    0.01
  ADA 40 mg Q2W±MTX                        27                                                                                              0.3                                                                               
  **tsDMARD tapering**                                                                                                                                                                                                       
  Takeuchi 2019 (RA-BEYOND)[@R125]         CDAI ≤10                                                                                        12                Continued BARI 4 mg±csDMARD                      281   93%      \<0.001
  BARI Step-down 2 mg±csDMARD              278                                                                                             83%                                                                               

Δ, change from baseline; ACR, American College of Rheumatology; ADA, adalimumab; BARI, baricitinib; bDMARD, biological disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; CZP, certolizumab pegol; DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; ETN, etanercept; EULAR, European League against Rheumatism; GC, glucocorticoid; INF, infliximab; LEF, leflunomide; mTSS, modified total Sharp Score; MTX, methotrexate; MTX, methotrexate; PLC, placebo; SJC, swollen joint count; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; tsDMARD, targeted synthetic DMARD.

Tapering and stopping csDMARDs or GCs {#s3-9}
-------------------------------------

MUSICA, a double-blind, non-inferiority RCT (low RoB) investigated randomised MTX dosage reduction to 7.5 mg/week compared with continuation of 20 mg/week in MTX-IR patients with open-label ADA initiation. The mean DAS28-CRP was statistically lower in the standard-dose group (3.75 vs 4.12, p=0.014) and non-inferiority of high versus low MTX dosage was therefore not shown (ΔDAS28-CRP 0.37 (95% CI 0.07 to 0.66) at week 24; NI-margin: 15%=0.56).[@R107] Thus, a mandatory dose reduction from 20 to 7.5 mg MTX weekly seems too low for combination therapy with a TNFi.

A Canadian open-label RCT (high RoB) reported no differences in DAS28-ESR change after patients treated with certolizumab plus csDMARD had been randomised to continue combination therapy or discontinue csDMARDs (−2.1 vs −2.1).[@R108]

The SEMIRA trial (conference abstract) investigated patients treated with TCZ ±csDMARD therapy who also had stable GC therapy of 5 mg/day, comparing blinded tapering of GCs with continuation of GCs. A significant increase of disease activity (ΔDAS28-ESR) was seen in the discontinuation group compared with continuation (0.613, 95% CI 0.346 to 0.879, p\<0.001). Sixty-six per cent of patients discontinuing remaining in stable DAS28 ≤3.2 without experiencing disease flares, compared with 77% (RR 0.833, 95% CI 0.714 to 0.972, p=0.021) in the stable GC group.[@R111]

Several trials (one low RoB, one unclear RoB, one high RoB) showed non-inferiority of MTX tapering versus continuation in patients receiving ongoing (long-term) TCZ therapy.[@R112]

A substudy of the CareRA study investigated randomised step-down from COBRA Avant-Garde (MTX+LEF + initial prednisone 30 mg step-down) to either MTX (15 mg/week) or LEF (20 mg/day) monotherapy if they achieved an DAS28-CRP ≤3.2 after treatment induction during period of 40--52 weeks of therapy. After 65 weeks, significantly more patients achieved DAS28-CRP \<2.6, CDAI ≤10 or SDAI ≤11 in the MTX arm (30/32, 93.8%; 32/32, 100%; 32/32, 100% respectively) than in the LEF arm (19/26, 73.1%, p=0.031; 21/26, 80.8%, p=0.009; 22/26, 84.6%, p=0.021)[@R115] bDMARD tapering.

The POET study, a large open-label RCT (high RoB) randomised patients in stable low disease activity for 6 months (DAS28-ESR ≤3.2 or based on rheumatologists' impression) to either stop or continue their TNFi therapy, comparing proportions of patients experiencing a disease flare (DAS28-ESR ≥3.2 + DAS28-ESR change from baseline \>0.6) during 12 months. About 20% of patients could stop their TNFi therapy without experiencing a flare, but among those who continued TNFi therapy 50% did not experience a flare (TNFi stopping: 18.2% vs TNFi continuation: 51.2%, p\<0.001; HR 3.50; 95% CI 2.60 to 4.72).[@R117]

In C-OPERA, Japanese patients discontinued or continued certolizumab pegol after achieving DAS28-ESR ≤3.2 at week 52. At week 104, 29.3% of patients who stopped certolizumab pegol could maintain SDAI remission, compared with 41.5% of patients continuing (p=0.026). Significantly more radiographic progression occurred in patients who stopped certolizumab until week 104 (ΔmTSS at week 104 0.66 vs 3.01, p=0.001).[@R119]

In C-EARLY, a trial investigating certolizumab +MTX in csDMARD naive patients with early RA, patients who achieved DAS28-ESR≤3.2 at year 1 were either continued on CZP every 2 weeks, increased dosing interval of CZP (to every 4 weeks) or stopped CZP completely. Although the trial failed to meet its primary endpoint (% of patients in DAS28-ESR≤3.2 without flare at week 104), similar results for CZP Q2W versus interval prolongation to CZP every 4 weeks (48.8% vs 53.2%, p=0.112) were seen. Furthermore, 39.2% of patients could stop CZP completely and maintain DAS28-ESR ≤3.2 but the difference compared with continuation was significant (48.8% vs 39.2%, p=0.041).[@R120]

Further studies investigated the discontinuation of TCZ after combination therapy with MTX (SURPRISE study) and achieving DAS28-ESR \<2.6: sustained DAS28-ESR \<2.6 and DAS28-ESR ≤3.2 rates were more frequent in patients receiving concomitant MTX compared with TCZ monotherapy after 104 weeks (24% vs 14%, p=0.005; 55% vs 27%, p=0.005).[@R121] Tapering TNFi dose by 33% in patients with DAS28-ESR ≤3.2 for 3 months did not lead to increased flare rates (12% vs 16%, HR: 0.90, 95% CI 0.23 to 3.48, p=0.873), reducing the TNFi dose by 66% resulted in not statistically significantly different flare rates (DAS28-ESR \>3.2 and ΔDAS28-ESR ≥0.6) compared with treatment continuation (29% vs 16%, HR 2.52, 95% CI 0.85 to 7.48, p=0.097).[@R122]

A novel tapering strategy, using a biomarker, matrix metalloproteinase (MMP-3), or combined SDAI +MMP-3-guided tapering of bDMARDs in patients achieving SDAI ≤3.3 and normalisation of MMP-3 showed non-inferiority at week 52 as compared with just clinically guided maintenance of SDAI ≤3.3.[@R123] Open-label interval prolongation in patients with high ADA trough levels (defined as \>8 µg/mL) did not lead to increased disease activity (using DAS28-ESR, CDAI or SDAI).[@R124]

Tapering of tsDMARDs {#s3-10}
--------------------

The RA-BEYOND study randomised patients from four trials of BARI at 4 mg who had achieved stable CDAI ≤10 to either continue BARI 4 mg or reduce dose to 2 mg. While more patients who continued full dose maintained CDAI low disease activity compared with those who reduced the dose (93% vs 83%, p\<0.001 at 3 months; 87% vs 75%, p\<0.001, at 6 months; 80% vs 67%, p\<0.01 at 12 months for BARI 4 mg continuation vs dose reduction to BARI 2 mg, respectively), a majority of patients maintained their good disease state despite dose reduction. Further, in patients being in CDAI ≤2.8 at randomisation, fewer patients lost their disease activity state. Of those who flared after dose reduction, the majority (66.7%) regained their CDAI \<10 state within 24 weeks after dose increase to 4 mg. Thirteen of the 16 patients not regaining their CDAI \<10 state after 24 weeks were able to do so at a subsequent time point.[@R125]

Combined bDMARDs and csDMARDs tapering and/or stopping {#s3-11}
------------------------------------------------------

IMPROVED, a Dutch strategy trial (high RoB) aimed at drug free remission in patients with early RA and undifferentiated arthritis. After 5 years, 15%--20% (p=0.374) of patients could achieve drug-free remission.[@R126]

Dose reduction (by 50%) or stopping either csDMARDs, bDMARDs or both compared with dose continuation was investigated in a study of patients achieving stable DAS28-ESR \<2.6 for at least 6 months (high RoB). In the control group 6.5% of patients flared, while 42%--77% flared after dose reduction or stopping therapy completely.[@R127]

The TARA study compared csDMARD tapering with bDMARD tapering in patients who had long-standing combination therapy and found no significant differences in the flare (defined as DAS44 \>2.4 and/or SJC \>1) ratio between both groups (HR 0.91; 95% CI 0.68 to 1.22; p=0.55).[@R128]

Discussion {#s4}
==========

This SLR was performed to inform the task force for the 2019 update of the EULAR recommendations for the management of RA on the efficacy of various DMARDs as presented in publications from 2016 to March 2019. These publications covered a total of 32 DMARDs.

The SLR confirmed the high efficacy of csDMARD plus GC combination therapy as well as the efficacy of TNFi, IL-6Ri, ABA and rituximab as well as bsDMARDs in csDMARD (including MTX) IR patients. With respect to bsDMARDs, switch (including multiple switch) studies between bs and boDMARDs confirmed long-term safety and efficacy of biosimilars. Like bDMARDs, JAKi are efficacious in patients with RA. Several trials compared one bDMARD class (usually TNFi agents) with bDMARDs of other classes revealing similarity of response. Likewise, head-to-head trials between JAKi and anti-TNF did not reveal clinically important differences regarding efficacy.

In patients who failed a TNFi or other bDMARDs, tsDMARDs and also bDMARDs of the same or other classes revealed generally similar clinical efficacy[@R4] or relatively small differences.[@R68] Of interest (and part of the previous research agenda), sarilumab, an anti-IL-6R antibody, showed efficacy in patients who had an IR to TCZ, another IL-6Ri,[@R67] and in a study published after this SLR, TNFi showed efficacy after failure of JAKi.[@R129]

A strategy trial comparing treatment aimed at clinical remission to therapy aimed at remission by MRI showed no difference in clinical outcomes, but more adverse events and more costs in the imaging group, further confirming that stringent clinical remission is a sufficient treatment target and that imaging remission not only fails to convey better efficacy, but may constitute a potentially dangerous and costly overtreatment.[@R6]

Tapering studies revealed that dose reduction of JAKi and bDMARDs is feasible and that when starting dose reduction in sustained stringent remission less patients flare when compared with start of tapering just in sustained low disease activity.[@R125] Importantly, patients who flare can mostly (70%--80%) regain their prior good response.

The results of this SLR were presented to the task force and, together with the safety SLR,[@R8] formed the basis for the update of the EULAR RA management recommendations.
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